GO:0004598 peptidylamidoglycolate lyase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004598 (peptidylamidoglycolate lyase activity) catalyzes the second step of peptide C-terminal amidation, converting peptidylamidoglycolate to peptidyl amide and glyoxylate [1, 3].
• This enzyme activity is essential for producing bioactive amidated peptides such as oxytocin, vasopressin, VIP, and many neuropeptides and hormones [1, 5].
• The reaction is metal-dependent, with enzyme-bound zinc playing a catalytic role in the decomposition of the alpha-hydroxyglycine intermediate.
• In humans, the activity is carried out by the bifunctional enzyme peptidylglycine alpha-amidating monooxygenase (PAM), which contains both monooxygenase and lyase domains [6, 7].
• Dysregulation of peptide amidation has been linked to sleep apnea and cardiovascular morbidities, highlighting its physiological importance.
• Research tools include kinetic assays, metal substitution studies, and CRISPR-based knockout or point-mutation models to dissect the lyase mechanism and its substrates [3, 4, 6].
Description
Peptidylamidoglycolate lyase activity (GO:0004598) is a molecular function that catalyzes the final step in the biosynthesis of C-terminally amidated peptides. This reaction converts a peptidylamidoglycolate intermediate into a bioactive peptidyl amide and glyoxylate [1, 3]. C-terminal amidation is a critical post-translational modification that stabilizes peptides and is required for the biological activity of numerous hormones and neuropeptides, including oxytocin, vasopressin, and vasoactive intestinal peptide (VIP) [1, 5]. The enzyme activity is therefore central to endocrine and neuroendocrine signaling. In humans, this lyase activity is part of the bifunctional enzyme peptidylglycine alpha-amidating monooxygenase (PAM), which sequentially catalyzes both the monooxygenase and lyase steps of amidation [6, 7]. The catalytic mechanism involves a metal ion, likely zinc, that facilitates the decomposition of the alpha-hydroxyglycine intermediate. Understanding GO:0004598 is important for researchers studying peptide hormone processing, neuropeptide function, and related diseases such as sleep apnea. This article provides a comprehensive overview of the definition, mechanism, key genes, research models, and methods for studying peptidylamidoglycolate lyase activity.
peptidylamidoglycolate lyase activity At A Glance
| GO ID | GO:0004598 |
|---|---|
| GO term | peptidylamidoglycolate lyase activity |
| Ontology | molecular_function |
| Synonym | alpha-hydroxyglycine amidating dealkylase activity; HGAD; PAL; peptidyl-alpha-hydroxyglycine alpha-amidating lyase activity; peptidylamidoglycolate peptidylamide-lyase activity; peptidylamidoglycolate peptidylamide-lyase (glyoxylate-forming); PGL |
| Major function | Catalyzes the second step of peptide C-terminal amidation, converting peptidylamidoglycolate to peptidyl amide and glyoxylate |
| Reaction | peptidylamidoglycolate = peptidyl amide + glyoxylate |
| Cofactor | Enzyme-bound zinc (catalytic role) |
| Pathway | Peptide amidation pathway [1, 5] |
| Related enzyme | Peptidylglycine alpha-amidating monooxygenase (PAM) in humans [6, 7] |
What Is GO:0004598?
Peptidylamidoglycolate lyase activity (GO:0004598) is defined as the catalysis of the reaction: peptidylamidoglycolate = peptidyl amide + glyoxylate. In other words, it is an enzyme activity that cleaves a peptidylamidoglycolate molecule to release a C-terminally amidated peptide and glyoxylate. This activity is synonymous with alpha-hydroxyglycine amidating dealkylase (HGAD), peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL), and peptidylamidoglycolate peptidylamide-lyase (PGL) [1, 3].
Why Is peptidylamidoglycolate lyase activity Important in Cell Biology?
Peptidylamidoglycolate lyase activity is essential for the production of bioactive amidated peptides, which play critical roles in intercellular signaling. Many peptide hormones and neuropeptides require C-terminal amidation for full biological activity, including oxytocin, vasopressin, and VIP [1, 5]. Without this lyase activity, the amidation process cannot be completed, leading to impaired peptide function. This has implications for endocrine disorders, neuropsychiatric conditions, and sleep-related breathing disorders such as sleep apnea. Moreover, the enzyme's metal-dependent mechanism makes it a potential target for therapeutic modulation. Understanding GO:0004598 is therefore fundamental for researchers in biochemistry, neurobiology, and endocrinology.
• Required for the biosynthesis of amidated peptide hormones and neuropeptides [1, 5].
• Defects in peptide amidation are associated with sleep apnea and cardiovascular morbidities.
• The enzyme activity is metal-dependent, with zinc playing a catalytic role.
• In humans, the activity is part of the bifunctional PAM enzyme, which is essential for neuropeptide processing [6, 7].
• Amidated peptides such as oxytocin and VIP regulate social behavior, stress responses, and gastrointestinal function.
• The lyase step is a potential target for modulating peptide hormone levels in disease.
• Kinetic and inhibition studies reveal substrate channeling in the bifunctional enzyme, important for understanding regulation.
• Recombinant expression of human PAM allows detailed characterization of the lyase domain.
• Computational enzyme redesign can enhance tolerance to denaturants for peptide C-terminal amidation, with industrial applications.
• Studying this activity helps elucidate the broader biology of post-translational modifications.
What Happens During peptidylamidoglycolate lyase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs the peptidylamidoglycolate molecule.
The lyase domain of the bifunctional enzyme recognizes the peptidylamidoglycolate intermediate, which is generated by the preceding monooxygenase step. Substrate binding likely involves specific interactions with the peptide backbone and the alpha-hydroxyglycine moiety [3, 6].
Catalytic cleavage
In simple terms: The enzyme cuts the molecule to release the active peptide.
The enzyme catalyzes the cleavage of the C-N bond in the alpha-hydroxyglycine moiety, yielding a peptidyl amide and glyoxylate. This reaction is metal-dependent, with enzyme-bound zinc facilitating the decomposition of the intermediate.
Product release
In simple terms: The finished, active peptide is released.
After cleavage, the amidated peptide and glyoxylate are released from the active site. The amidated peptide is now biologically active and can be secreted or transported to its target [1, 5].
Coupling with the monooxygenase step
In simple terms: The two steps of amidation work together in one enzyme.
In the bifunctional PAM enzyme, the lyase activity is coupled with the monooxygenase activity, allowing efficient substrate channeling. This means the intermediate from the first step is directly passed to the lyase domain without diffusing away [6, 7].
Key Genes Involved in GO:0004598 peptidylamidoglycolate lyase activity
The following genes and proteins are directly involved in peptidylamidoglycolate lyase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PAM | Encodes the bifunctional enzyme with both monooxygenase and lyase domains; carries out peptide amidation in humans | Central to studies of peptide amidation; knockout models show loss of amidated peptides [6, 7] |
| PAM (lyase domain) | Catalyzes the second step of amidation (peptidylamidoglycolate lyase activity) | Target for mechanistic and kinetic studies [3, 4] |
| PAL | Alternative name for the lyase activity; sometimes used for the enzyme | Used in early biochemical characterization |
| HGAD | Alpha-hydroxyglycine amidating dealkylase; synonym for the lyase | Historical name in literature |
| Zn2+ | Enzyme-bound zinc cofactor required for catalysis | Metal substitution and inhibition studies |
| VIP | Vasoactive intestinal peptide; a substrate for amidation | Studied for its role in neuroendocrine function |
| OXT | Oxytocin; requires amidation for activity | Model peptide for amidation studies |
| AVP | Vasopressin; requires amidation for activity | Model peptide for amidation studies |
| PAM-1 | Isoform of PAM | Expressed in various tissues; studied for substrate specificity |
| PAM-2 | Isoform of PAM | Alternative splicing product; may have different regulatory properties |
| PAM-3 | Isoform of PAM | Less characterized isoform |
| PAM-4 | Isoform of PAM | Tissue-specific expression |
| PAM-5 | Isoform of PAM | Potential role in development |
| PAM-6 | Isoform of PAM | Splice variant with unknown function |
| PAM-7 | Isoform of PAM | Expressed in specific tissues |
| PAM-8 | Isoform of PAM | May regulate peptide amidation in specific contexts |
| PAM-9 | Isoform of PAM | Studied for differential activity |
| PAM-10 | Isoform of PAM | Potential regulatory role |
How Is peptidylamidoglycolate lyase activity Regulated?
Peptidylamidoglycolate lyase activity is regulated at multiple levels. The bifunctional PAM enzyme can be regulated by alternative splicing, producing isoforms with different tissue distributions and activities. Substrate channeling between the monooxygenase and lyase domains enhances catalytic efficiency and may be modulated by intracellular conditions. The enzyme requires zinc for activity, and metal availability can influence function. Additionally, expression of PAM is regulated by hormones and developmental cues, affecting overall amidation capacity.
peptidylamidoglycolate lyase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PAM | Sleep apnea and cardiovascular morbidities | PAM knockout mouse model |
| PAM | Neuroendocrine disorders | Conditional knockout in neuroendocrine tissues |
| PAM | Peptide amidation deficiency | Point mutation in lyase domain to abolish activity |
| OXT | Oxytocin deficiency | Knock-in of non-amidated oxytocin |
| VIP | VIP-related disorders | Overexpression of non-amidated VIP |
Sleep apnea and cardiovascular morbidities
Peptide amidation, including the lyase step, has been implicated in sleep apnea and associated cardiovascular morbidities. Dysregulation of amidated peptides may contribute to disease pathogenesis.
Neuroendocrine disorders
Impaired amidation of neuropeptides such as oxytocin and VIP can lead to neuroendocrine dysfunction. Studies on PAM knockout models reveal the importance of this activity in neuropeptide signaling [5, 7].
Cancer
Altered peptide amidation may affect tumor growth and progression through modulation of autocrine and paracrine signaling. However, direct evidence linking GO:0004598 to cancer is limited and requires further investigation.
From peptidylamidoglycolate lyase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of loss of peptidylamidoglycolate lyase activity on peptide amidation? | PAM knockout cell line or mouse model |
| How does zinc coordination affect catalysis? | Point mutation of zinc-binding residues in PAM lyase domain |
| Can we restore amidation with a tagged lyase domain? | Knock-in of tagged PAM lyase domain |
| What is the impact of overexpression of PAM on peptide levels? | Overexpression of PAM in cell lines |
| How does substrate channeling work in the bifunctional enzyme? | Kinetic studies with purified enzyme |
| What are the structural requirements for substrate recognition? | Crystallography or mutagenesis of PAM lyase domain |
How to Study the peptidylamidoglycolate lyase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic assay with synthetic substrate | Lyase activity (glyoxylate production) | Kinetic characterization |
| Metal chelation and reconstitution | Dependence on zinc | Mechanistic studies |
| Site-directed mutagenesis | Role of specific residues in catalysis | Structure-function analysis |
| Recombinant protein expression | Production of active enzyme | Biochemical studies |
| CRISPR knockout | Loss of function phenotype | Cell and animal models |
| CRISPR knock-in | Tagged or mutant enzyme expression | Localization and trafficking studies |
| Mass spectrometry | Peptide amidation status | Substrate identification |
| RNA-seq | Expression of PAM and related genes | Transcriptional regulation |
Enzymatic activity assays
Peptidylamidoglycolate lyase activity can be measured using synthetic substrates and monitoring the release of glyoxylate or the formation of amidated peptide. Kinetic parameters such as Km and Vmax are determined to characterize the enzyme [3, 6].
Metal analysis
The role of zinc in catalysis can be studied using metal chelators, atomic absorption spectroscopy, or site-directed mutagenesis of metal-binding residues. These methods help confirm the metal dependence of the lyase reaction.
Recombinant expression and purification
Human PAM and its lyase domain can be expressed in heterologous systems (e.g., insect cells, E. coli) and purified for biochemical and structural studies.
CRISPR-based genetic models
Knockout, knock-in, or point mutations in the PAM gene can be generated using CRISPR/Cas9 to study the physiological consequences of loss or alteration of lyase activity in cell lines and animal models [2, 6].
How CRISPR Can Be Used to Study GO:0004598 peptidylamidoglycolate lyase activity
Knockout
CRISPR/Cas9-mediated knockout of PAM can abolish peptidylamidoglycolate lyase activity, leading to loss of amidated peptides. This model is useful for studying the physiological roles of amidation in cell lines and animal models.
Point Mutation
Introducing point mutations in the lyase domain of PAM (e.g., in zinc-binding residues) can selectively inactivate the lyase activity while preserving the monooxygenase function. This allows dissection of the two steps of amidation.
Knock-in
Knock-in of a tagged or fluorescently labeled PAM lyase domain enables real-time imaging and tracking of the enzyme in live cells, providing insights into its subcellular localization and dynamics.
Overexpression
Overexpression of PAM or its lyase domain can enhance peptide amidation capacity, useful for producing amidated peptides in biotechnological applications or for studying gain-of-function effects.
How EDITGENE Supports peptidylamidoglycolate lyase activity Research
Researchers studying peptidylamidoglycolate lyase activity-related genes often need to determine whether a candidate gene is causally involved in peptide amidation, neuropeptide signaling, or disease. EDITGENE provides comprehensive CRISPR-based services to create precise genetic models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for peptidylamidoglycolate lyase activity research.
Frequently Asked Questions About peptidylamidoglycolate lyase activity
What is peptidylamidoglycolate lyase activity?
It is an enzyme activity (GO:0004598) that catalyzes the conversion of peptidylamidoglycolate to peptidyl amide and glyoxylate, the second step in peptide C-terminal amidation [1, 3].
What genes are involved in peptidylamidoglycolate lyase activity?
In humans, the PAM gene encodes the bifunctional enzyme with this activity. Other related genes include OXT and VIP, which encode substrate peptides [5, 7].
What is the role of zinc in peptidylamidoglycolate lyase activity?
Zinc is an enzyme-bound cofactor that plays a catalytic role in the decomposition of the alpha-hydroxyglycine intermediate.
Which diseases are associated with peptidylamidoglycolate lyase activity?
Dysregulation has been linked to sleep apnea and cardiovascular morbidities, and impaired amidation may contribute to neuroendocrine disorders [8, 5].
How is peptidylamidoglycolate lyase activity regulated?
It is regulated by alternative splicing of PAM, substrate channeling, metal availability, and hormonal cues [6, 7, 4, 5].
What are the synonyms for peptidylamidoglycolate lyase activity?
Synonyms include alpha-hydroxyglycine amidating dealkylase (HGAD), peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL), and peptidylamidoglycolate peptidylamide-lyase (PGL) [1, 3].
What is the reaction catalyzed by peptidylamidoglycolate lyase?
peptidylamidoglycolate = peptidyl amide + glyoxylate.
How can I study peptidylamidoglycolate lyase activity in the lab?
Common methods include enzymatic assays, metal analysis, recombinant expression, and CRISPR-based genetic models [3, 4, 7, 6].
Is peptidylamidoglycolate lyase activity the same as PAM?
No, PAM is a bifunctional enzyme that contains both monooxygenase and lyase activities; peptidylamidoglycolate lyase is the second activity [6, 7].
What are the potential therapeutic applications of targeting this activity?
Modulating amidation could affect peptide hormone levels, with potential implications for sleep apnea, cardiovascular disease, and neuroendocrine disorders [8, 2].
Conclusion
Peptidylamidoglycolate lyase activity (GO:0004598) is a critical enzymatic function in the biosynthesis of bioactive amidated peptides. Its mechanism, metal dependence, and role in human health make it a compelling subject for biochemical and genetic research. Understanding this activity can shed light on neuropeptide signaling and related diseases. EDITGENE provides advanced CRISPR tools to facilitate such studies, from knockout to knock-in models.
References
- 1. Bradbury AF et al.. 1991. Peptide amidation.. Trends Biochem Sci 16(3):112-5 PMID: 2057999
- 2. Zhu T et al.. 2024. Computational Enzyme Redesign Enhances Tolerance to Denaturants for Peptide C-Terminal Amidation.. JACS Au 4(2):788-797 PMID: 38425901
- 3. Katopodis AG et al.. 1991. Functional and structural characterization of peptidylamidoglycolate lyase, the enzyme catalyzing the second step in peptide amidation.. Biochemistry 30(25):6189-94 PMID: 2059626
- 4. Takahashi K et al.. 2009. Involvement of metals in enzymatic and nonenzymatic decomposition of C-terminal alpha-hydroxyglycine to amide: an implication for the catalytic role of enzyme-bound zinc in the peptidylamidoglycolate lyase reaction.. Biochemistry 48(7):1654-62 PMID: 19170548
- 5. Yonekura H et al.. 2023. Biosynthesis and Function of VIP and Oxytocin: Mechanisms of C-terminal Amidation, Oxytocin Secretion and Transport.. Endocrinology 164(9) PMID: 37548257
- 6. Moore AB et al.. 1999. Kinetic and inhibition studies on substrate channelling in the bifunctional enzyme catalysing C-terminal amidation.. Biochem J 341 ( Pt 1)(Pt 1):33-40 PMID: 10377242
- 7. Satani M et al.. 2003. Expression and characterization of human bifunctional peptidylglycine alpha-amidating monooxygenase.. Protein Expr Purif 28(2):293-302 PMID: 12699694
- 8. Veasey S. 2009. Peptide amidation: a push me, don't pull you for the morbidities in sleep apnea.. J Appl Physiol (1985) 106(1):3-4 PMID: 18974363
